On 5 October 2026, QINGLING MOTORS (01122.HK) signed a repurchase deal with Haitong Unitrust (01905.HK) for 30 new energy vehicles, capped at RMB 12,636,030.
On 5 October 2026, CN HEALTH TECH (01069.HK) said its annual results for the year ended 30 June 2026 are delayed, with shares suspended since 2 October 2026.
On 5 October 2026, VISEN PHARMA-B (02561.HK) said Ms. Sherrie Lynn Glass has stepped down as a non-executive director, with no Board disagreement.
On 5 October 2026, FW FASHION INT (02528.HK) said its Macau Popmart store agreement will cease on 21 December 2026; such stores made up about 22% of revenue.
On 5 October 2026, CSPC PHARMA (01093.HK) said it will present 8 clinical trial updates at the ESMO Congress 2026 in Madrid, two of them as LBAs.
On 5 October 2026, GAPACK (00468.HK) said the Listing Committee decided to cancel its listing, with delisting due on 20 October 2026 if no review is sought.
On 5 October 2026, SIHUAN PHARM (00460.HK) said five new specifications of its skin booster Dongyan were approved for launch in China by the NMPA.
On 5 October 2026, WYNN MACAU (01128.HK) announced that it granted awards over a total of 317,938 shares to 315 employees of the Group under its Employee Share Ownership Plan adopted on 25 May 2023, representing approximately 0.01% of its issued share capital as at the date of the announcement, at a nil purchase price.
On 5 October 2026, FW FASHION INT (02528.HK) announced that its existing retail store management agreement arrangement with Pop Mart for operating Pop Mart stores in Macau will terminate with effect from 21 December 2026, with revenue from those stores accounting for approximately 22% of the Group's total revenue for the nine months ended 30 September 2026.
On 5 October 2026, ASMPT (00522.HK) announced that Ms. Xiao Jieyun has resigned as an independent non-executive director and chairman of the audit committee with effect from 1 January 2027, as the expected listing of another company on whose board she serves will cause the number of her listed company directorships to exceed the applicable limit.
On 5 October 2026, SIHUAN PHARM (00460.HK) announced that five new specifications of the injectable sodium hyaluronate complex solution (product name: Dongyan), developed by its subsidiary Meiyan Space, have been approved for marketing by China's National Medical Products Administration, namely 0.75 mL, 1.25 mL, 1.75 mL, 2.25 mL and 2.75 mL per vial.
On 5 October 2026, MAOYAN ENT (01896.HK) announced that its board approved a plan to exercise the share buy-back mandate granted by shareholders at the AGM held on 23 June 2026, under which the Company may spend up to approximately HKD 250 million to repurchase shares on the open market from the date of the announcement until the date of its next AGM in 2027.
On 5 Oct 2026, LVGEM CHINA (00095.HK) signed an RSA on 30 Sept for its offshore restructuring and the winding-up petition was adjourned to 6 April 2027.
On 5 Oct 2026, AGILE GROUP (03383.HK) is close to finalising an RSA for US$5.183bn of offshore debt, with ~64.6% of post-restructuring shares as consideration.
On 4 Oct 2026, SINCERE (00244.HK) said its Central store will close around early December after lease renewal talks failed; it will keep the Mong Kok store.
On 4 Oct 2026, BUD APAC (01876.HK) flagged ~US$82m of Q3 charges: ~US$52m reorganisation withholding tax and ~US$30m India receivables provision.
